## Edgar Filing: INOVIO PHARMACEUTICALS, INC. - Form 4

INOVIO PHARMACEUTICALS, INC Form 4 May 16, 2016	2.			
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue <b>STATEMENT O</b> <b>STATEMENT O</b>	S SECURITIES AND EXCHANGE ( Washington, D.C. 20549 F CHANGES IN BENEFICIAL OW SECURITIES Section 16(a) of the Securities Exchang Public Utility Holding Company Act o of the Investment Company Act of 194	<b>NERSHIP OF</b> ge Act of 1934, f 1935 or Section	OMB APPROVAL OMB 3235-0287 Number: January 31, 2005 Estimated average burden hours per response 0.5	
(Print or Type Responses) 1. Name and Address of Reporting Person <u>*</u> Wysenski Nancy	2. Issuer Name <b>and</b> Ticker or Trading Symbol INOVIO PHARMACEUTICALS,	Issuer	Reporting Person(s) to c all applicable)	
(Last) (First) (Middle) 660 W. GERMANTOWN PIKE, SUITE 110	INC. [INO] 3. Date of Earliest Transaction (Month/Day/Year) 05/13/2016	_X_ Director Officer (give t below)	itle 10% Owner Other (specify below)	
(Street) 4. If Amendment, Date Original 6. Individual or J Filed(Month/Day/Year) Applicable Line) _X_ Form filed by			oint/Group Filing(Check One Reporting Person More than One Reporting	
(City) (State) (Zip)	Table I - Non-Derivative Securities Acc	quired, Disposed of,	or Beneficially Owned	
	emed 3. 4. Securities	5. Amount of 6 Securities F Beneficially ( Owned I	5. Ownership 7. Nature of Form: Direct Indirect D) or Beneficial Indirect (I) Ownership Instr. 4) (Instr. 4)	
Common Stock		5,000 I	D	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount Underlying Securitie (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amou or Numb of Sha
Restricted Stock Unit	(1)	05/13/2016		А	10,000	<u>(1)</u>	<u>(1)</u>	Common Stock	10,0
Common Stock Options	\$ 9.33	05/13/2016		А	10,000	05/13/2017(2)	05/13/2026	Common Stock	10,0

## Edgar Filing: INOVIO PHARMACEUTICALS, INC. - Form 4

## **Reporting Owners**

Reporting Owner Name / Address		Relationships				
	Director	10% Owner	Officer	Other		
Wysenski Nancy 660 W. GERMANTOWN PIKE SUITE 110 PLYMOUTH MEETING, PA 19462	X					
Signatures						
/s/ Nancy J. Wysenski 05/16/20	16					

<u>\*\*</u>Signature of Reporting Person

Date

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 13, 2017.
- (2) Options to vest 100% on May 13, 2017.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.